01 1Eli Lilly Kinsale Limited
01 1Pirtobrutinib
01 1U.S.A
NDC Package Code : 63419-0739
Start Marketing Date : 2022-02-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Pirtobrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pirtobrutinib, including repackagers and relabelers. The FDA regulates Pirtobrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pirtobrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pirtobrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pirtobrutinib supplier is an individual or a company that provides Pirtobrutinib active pharmaceutical ingredient (API) or Pirtobrutinib finished formulations upon request. The Pirtobrutinib suppliers may include Pirtobrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Pirtobrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pirtobrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pirtobrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pirtobrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pirtobrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pirtobrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pirtobrutinib suppliers with NDC on PharmaCompass.
We have 1 companies offering Pirtobrutinib
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
